Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Single-arm Phase II Clinical Study of Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients

NCT06032052 is registered in ClinicalTrials.gov with Hubei Cancer Hospital as lead sponsor.

NCT NCT06032052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06032052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Single-arm Phase II Clinical Study of Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
Lead sponsor
Hubei Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
February 1, 2024
Completion date
September 30, 2027
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

elderly patients, metastatic lung cancer